Author

Julie Lafontaine

Centre Hospitalier de l’Université de Montréal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

Philip WongiD· 2 shared Cynthia M. MénardiD· 1 shared Elena Refet-MollofiD· 1 shared Mame Daro FayeiD· 1 shared Rodin ChermatiD· 1 shared Run Zhou YeiD· 1 shared Thomas GervaisiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Philip WongORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent manner

Mame Daro Faye, Julie Lafontaine, Philip Wong, Cynthia M. Ménard

This study shows Xevinapant enhances radiotherapy-induced cell death in TNBC cells, with TNFα playing a key role in this effect.

bioRxiv · Oct 1, 2026 · PreprintCancer Biology

Hypoxic-Core (HyCo) Spheroids Recapitulate Hallmarks of Clinical Hypoxia: A Simple Chip-Based Method for Translational Oncology

Elena Refet-Mollof, Rodin Chermat, Julie Lafontaine, Run Zhou Ye, Thomas Gervais, Philip Wong

This paper introduces a microfluidic device to generate hypoxic-core spheroids that mimic clinical hypoxia in cancer, showing increased resistance to therapy and invasiveness.

bioRxiv · Apr 3, 2025 · PreprintCancer Biology